Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 7,089 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Neoplasms
Interventions: Plavix, Aspirin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Chemotherapy Effect, Exercise Therapy, Cognitive Change
Interventions: High-Intensity Intervals Training, Attention Control; Behavioral · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions: cyclophosphamide, paclitaxel, trastuzumab, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 20 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Grand Island, Nebraska • Omaha, Nebraska

Conditions: Breast Cancer
Interventions: Reader Study - Imagio Ultrasound, Reader Study Imagio Ultrasound + Optoacoustic Imaging, Mammography; Device
Lead sponsor: Seno Medical Instruments Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: iShare; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Female Breast Cancer
Interventions: docetaxel + cyclophosphamide + pegfilgrastim; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Triple-negative Breast Cancer
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Device: smartphone; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Triple Negative Breast Cancer
Interventions: Merck 3475 Pembrolizumab, Intraoperative radiation therapy (IORT); Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Maywood, Illinois • New York, New York

Conditions: Breast Cancer
Interventions: chemotherapy, radiation therapy; Drug · Radiation
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 166
States / cities: Antioch, California • Fremont, California • Hayward, California + 122 more

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions: LMB-9 immunotoxin; Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions: ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox, flow cytometry, immunoenzyme technique; Drug · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate, Brain, Breast, Lung, Endometrial
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 90 Years
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Tumor
Interventions: DOSI; Device
Lead sponsor: Beckman Laser Institute and Medical Center; Other
Eligibility: 21 Years to 80 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Costa Mesa, California • Irvine, California • San Francisco, California

Conditions: Breast Cancer
Interventions: Tomosynthesis, Conventional; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years and older · Female only
Enrollment: 496 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hormone-sensitive Metastatic Breast Cancer
Interventions: OSI-906, Erlotinib, Letrozole, Goserelin; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Franklin, Tennessee • Nashville, Tennessee

Conditions: Solid Tumor, Adult
Interventions: FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Endocrine Therapy-Induced Alopecia, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Minoxidil, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Relapse, Resistant Cancer, Triple Negative Breast Cancer
Interventions: iC9-CAR.B7-H3 T Cell Therapy, cyclophosphamide, fludarabine; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
Interventions: Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46, Positron Emission Tomography; Procedure · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: doxorubicin hydrochloride, suramin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: counseling intervention, study of socioeconomic and demographic variables, management of therapy complications, psychosocial assessment and care; Other · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 6
States / cities: Ann Arbor, Michigan • New York, New York

Search by objective public record fields.

A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients

Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy

Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery

Optoacoustic Images Versus Imagio® Ultrasound

Clinician Communication About Sexual Health

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI

Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women